Whole genome sequencing revealed clinically relevant alterations missed by standard testing in MDS, identifying 21 novel high-confidence variants in 39% of cases, including key structural and prognostic drivers. Presented at #ASCO26 by Dr. Alex Bataller. @AlexBataller@garciamanero #EndCancer 9/12
🔑 KEY FINDING: 52% of patients showed immunophenotypic shifts after revumenib — often myeloid/stem-like → monocytic/myelomonocytic. Among MRD+ patients in remission, 67% had antigen expression changes vs. pre-treatment AML! 👇
@AlexBataller
MD Anderson is proud to be named #1 in the nation for cancer care in @USNews’“Best Hospitals” ranking.
Read more: https://t.co/6DKYn4XAp5
#BestHospitals#EndCancer
New in @LeukemiaJnl : Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors
https://t.co/9XOBGGdSPb
#leusm
It is with deep sorrow that we bid our brother @AlmanzaLeukMD farewell today. A brilliant leukemia physician @MDAndersonNews whose light shone so bright; the world is so much darker now.
Please donate to help his family, whom he supported, with costs: https://t.co/sNBnDHiM4a
👉👉👉It is with heavy heart that I share this news. Dr Almanza was the one of the most beautiful human beings I have ever met and a true light in the world. We will miss him dearly | @garciamanero@TapKadia | @jenweiying@NitinJainMD@AlexBataller 🙏
https://t.co/stBHcJyhDu